Quest Diagnostics
DGX | NYSE
$233.75
-$11.13 (-4.55%)
Sep 22, 2026, 12:31 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 11.04B | 9.87B | 9.25B | 9.88B | 10.79B | 9.44B |
Cost of Revenue | 7.51B | 6.63B | 6.2B | 6.45B | 6.58B | 5.8B |
Gross Profit | 3.52B | 3.24B | 3.07B | 3.43B | 4.21B | 3.63B |
Operating Income | 1.6B | 1.35B | 1.26B | 1.43B | 2.38B | 1.97B |
Interest Income | 13M | 25M | 11M | 10M | 1M | 3M |
Pretax Income | 1.36B | 1.19B | 1.16B | 1.28B | 2.68B | 1.96B |
Net Income | 992M | 871M | 854M | 946M | 2B | 1.43B |
Selling & General & Admin | 1.97B | 1.77B | 1.62B | 1.87B | 1.73B | 1.55B |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | -47M | 128M | 192M | 131M | 101M | 112M |
Operating Expenses | 1.92B | 1.9B | 1.81B | 2.01B | 1.83B | 1.66B |
Interest Expense | 277M | 226M | 163M | 148M | 152M | 166M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 9.43B | 8.53B | 7.99B | 8.46B | 8.41B | 7.47B |
Income Tax Expense | 314M | 273M | 248M | 264M | 597M | 460M |
Shares Outstanding (Basic) | 111M | 111M | 112M | 116M | 125M | 134M |
Shares Outstanding (Diluted) | 113M | 113M | 113M | 118M | 128M | 136M |
EPS (Basic) | 8.87 | 7.80 | 7.59 | 8.12 | 15.90 | 10.68 |
EPS (Diluted) | 8.75 | 7.69 | 7.52 | 7.98 | 15.53 | 10.52 |
EBITDA | 2.19B | 1.89B | 1.73B | 1.82B | 3.16B | 2.41B |
EBIT | 1.62B | 1.4B | 1.29B | 1.38B | 2.75B | 2.05B |
Depreciation & Amortization | 570M | 493M | 439M | 437M | 408M | 361M |
Add to Watchlist
Select watchlists to add or remove DGX